A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Forero-Torres, Andres [1 ]
Bartlett, Nancy L. [2 ]
Nasta, Sunita D. [3 ]
Northfelt, Donald [4 ]
Beaven, Anne [5 ]
Myint, Han [6 ]
Whiting, Nancy C. [7 ]
Drachman, Jonathan G. [7 ]
Moskowitz, Craig H. [8 ]
机构：
[1] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[3] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Mayo Clin Arizona, Scottsdale, AZ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Univ Colorado, Aurora, CO USA
[7] Seattle Genet Inc, Bothell, WA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：243 / 244
页数：2
相关论文
共 50 条
  • [21] Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
    Zhang, Yian
    Yuan, Ling
    Zhuang, Jingli
    Wang, Zhimei
    Zhang, Xuejiao
    Wang, Weiguang
    Liu, Peng
    BLOOD, 2023, 142
  • [22] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [23] Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Bieker, R
    Kessler, T
    Berdel, WE
    Mesters, RM
    ONCOLOGY REPORTS, 2003, 10 (06) : 1915 - 1917
  • [24] Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
    Nastoupil, Loretta J.
    Kuruvilla, John
    Chavez, Julio C.
    Bijou, Fontanet
    Witzig, Thomas E.
    Santoro, Armando
    Flinn, Ian W.
    Boccomini, Carola
    Kenkre, Vaishalee P.
    Corradini, Paolo
    Isufi, Iris
    Andorsky, David J.
    Klein, Leonard M.
    Greenwald, Daniel R.
    Sangha, Randeep
    Shen, Frank
    Hagner, Patrick
    Li, Yan
    Dobmeyer, Juergen
    Gong, Nian
    Uttamsingh, Shailaja
    Pourdehnad, Michael
    Ribrag, Vincent
    EJHAEM, 2022, 3 (02): : 394 - 405
  • [25] SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-PRELIMINARY RESULTS OF THE STORM TRIAL
    Witzens-Harig, M.
    Keller, U.
    Viardot, A.
    Buske, C.
    Hoenig, E.
    Crombe, A.
    Brandt, J.
    Meissner, J.
    Ho, A.
    La Rosee, P.
    Marks, R.
    Dreyling, M.
    Hess, G.
    HAEMATOLOGICA, 2016, 101 : 390 - 390
  • [26] Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria
    Aribi, Mourad
    Mesli, Naima
    Remla, Nesrine
    Sari, Badr-Eddine
    Taleb, Abdesselam
    Touhami, Hadj
    Bakadja, Mohamed Amine
    Zouaoui-Benhadji, Zahia
    Bouzid, Kamel
    Meguenni, Kaoual
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2010, 6 (01) : 41 - 46
  • [27] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
    Dickinson, Michael
    Briones, Javier
    Herrera, Alex F.
    Gonzalez-Barca, Eva
    Ghosh, Nilanjan
    Cordoba, Raul
    Rutherford, Sarah C.
    Bournazou, Eirini
    Labriola-Tompkins, Emily
    Franjkovic, Izolda
    Chesne, Evelyne
    Brouwer-Visser, Jurriaan
    Lechner, Katharina
    Brennan, Barbara
    Nueesch, Eveline
    DeMario, Mark
    Ruettinger, Dominik
    Kornacker, Martin
    Hutchings, Martin
    BLOOD ADVANCES, 2021, 5 (22) : 4762 - 4770
  • [29] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
    Matasar, M.
    Herrera, A. F.
    Kamdar, M.
    Mehta, A.
    Assouline, S.
    Fleury, I.
    Kim, T. M.
    Kim, W. S.
    Bosch, F.
    Radford, J.
    Flowers, C. R.
    Bu, L.
    Hong, W. -J.
    Sehn, L. H.
    HAEMATOLOGICA, 2017, 102 : 173 - 173
  • [30] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
12345